Brief Items of Interest, February 2017

Hair loss news 1st:

— In Aclaris Therapeutics’ latest webcast presentation from today (provided at the Leerink Partners 6th Annual International Healthcare Conference), the company’s CEO further elaborated on why they are so optimistic about “highly selective covalently bound JAK 3 inhibitors” helping patients with male pattern hair loss. Much more importantly, the CEO emphasized treating female hair loss and how that is even more distressing than male hair loss. You can listen to the whole presentation following registration, and also see the 42 slides in there. Principal sections are a little right after 16:30 minutes into the presentation and later on around 21:30 into the presentation. For after, a person asked a distinct question about covalently bound JAK three inhibitors and male pattern hair loss. The most interesting quotes from the CEO:

“Most importantly, androgenic alopecia. Even though that is traditionally not thought of as an inflammatory approach, what they were able to find is that the JAK inhibitors have been targeting the stem cell compartment in the hair follicle bulge and in fact prolonging and inducing anagen”.

“Being covalently bound…its got a a lot far better shot of not being as promiscous as the other JAK inhibitors“.

— Renowned Singapore primarily based venture capitalist Finian Tan is a major investor in Samumed. I did not recognize that he made the choice to invest in the organization so suddenly. In his own words: “Only twice in my life I have bet so huge on day one”. Poker champion, Samumed CEO Dr. Osman Kibar clearly has some hypnotic powers at his disposal.

— More developments in finding the genes behind baldness. On this weblog I have covered a number of other recent such developments, including this exciting a single from final year.

— On Hairsite, there is a fantastic question and answer session with Dr. Paul Kemp of HairClone. Dr. Kemp also did the exact same on here a handful of months ago.

— Soon after Hairsite’s revamp of its forum into a mobile friendly a single late last year, the Hair Transplant Network is preparing to do the very same to its intriguing forum.

— Numerous occasions during the past year, I have posted news about a variety of physicians providing an adipose (fat) cell plus PRP combo treatment for hair loss. It seems like this therapy was part of a US primarily based clinical trial, but I by no means did also much study into it. A new post on this pointed me towards the principal page for the actual website of the trials. They get in touch with it STRAAND , which stands for “Stromal Tissue Cell-enriched therapy of Androgenic Alopecia through Novel Deployment”. So far, six doctors are participating. Nonetheless, unlike in other trials, it appears like individuals are accountable for their personal expenditures.

— Replicel CEO Lee Buckler writes his 1st article for the Huffington Post: “Will 2017 be the year of Cell Therapies?“.

And now on to health-related items of interest:

— US patent office hands win in CRISPR battle to Broad Institute.

— Human gene editing receives US science panels assistance. If you have trouble accessing the site, an additional take here. One particular day later, a warning from ethicists.

— DARPA: We are on the cusp of merging human and machine.

— From the respected “The Economist” magazine: “Printed human physique parts could soon be obtainable for transplant“.

— The long quest to produce artificial blood may quickly be over.

— Trump vows to ease guidelines and regulations for drug makers.

— The tiny robots revolutionizing eye surgery.

— Personal computer lets fully paralyzed individuals speak for the 1st time.

— A lengthy article on Dr. Anthony Atala, with many images

— First human-pig chimeras developed.

— New study that supplies additional proof of caloric restriction and longevity.

The End of Hair Loss and Balding by 2020



Leave a Reply

Your email address will not be published. Required fields are marked *